{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:40:27Z","timestamp":1783086027857,"version":"3.54.6"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: The optimal duration of antibiotic treatment for extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae (ESBL-E) bloodstream infections (BSI) in intensive care unit (ICU) is not established. We aim to evaluate the frequency and clinical outcomesof a short appropriate antibiotic treatment (\u22647 days) (SAT) for ESBL-E BSI acquired in the ICU. We specifically assessed the rate of ESBL-E BSI relapse, and in-ICU mortality. Method: All patients who acquired ESBL-E BSI in three ICU in Northern France between January 2011 and June 2022 were included in a multicenter retrospective cohort study. The factors associated with prescribing short (SAT, \u22647 days) versus long (LAT, &gt;7 days) antibiotic treatment were analyzed. To evaluate the impact of SAT on mortality in the ICU, an estimation was applied using a Cox model with a time-dependent co-variable adjusted by inverse weighting of the propensity score. Results: In total, 379 patients were included. The proportion of patients receiving a SAT was 40% in the entire cohort and 25% in survivors beyond 7 days. In bivariate analysis, the factors associated with prescribing a SAT in survivors were shorter pre-bacteremia ICU stay (p = 0.005), lower proportion of chronic renal failure history (p = 0.034), cancer (p = 0.042), or transplantation (p = 0.025), less frequent exposure to carbapenem within 3 months (p = 0.015). There was a higher proportion of septic shock (p = 0.017) or bacteremia secondary to pneumonia (p = 0.003) in the group of survivors receiving a LAT. After adjustment, no difference in survival was found between the two groups (HR: 1.65, 95%CI: 0.91\u20133.00, p = 0.10). Conclusion: In our cohort, one quarter of patients with ESBL-E bacteremia acquired in the ICU surviving beyond 7 days were treated with a SAT. SAT did not appear to affect survival. Patients who could benefit from a SAT need to be better identified.<\/jats:p>","DOI":"10.3390\/antibiotics14040358","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T11:17:57Z","timestamp":1743506277000},"page":"358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimizing Antibiotic Treatment Duration for ESBL-Producing Enterobacteriaceae Bacteremia in ICU: A Multicentric Retrospective Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Camille","family":"Le Berre","sequence":"first","affiliation":[{"name":"Service de R\u00e9animation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Degrendel","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Houard","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation M\u00e9dicale, CHRU de Lille, 2 Avenue Oscar Lambret, 59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Benetazzo","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vach\u00e9e","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie, Centre Hospitalier de Roubaix, 11 Boulevard Lacordaire, 59100 Roubaix, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Georges","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-5466","authenticated-orcid":false,"given":"Frederic","family":"Wallet","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie, CHRU de Lille, 2 Avenue Oscar Lambret, 59000 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-5430","authenticated-orcid":false,"given":"Pierre","family":"Patoz","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Bortolotti","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation, Centre Hospitalier de Roubaix, 11 Boulevard Lacordaire, 59100 Roubaix, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-0357","authenticated-orcid":false,"given":"Saad","family":"Nseir","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Delannoy","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-0602","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Meybeck","sequence":"additional","affiliation":[{"name":"Service de R\u00e9animation et Maladies Infectieuses, Centre Hospitalier de Tourcoing, 135 Rue du Pr\u00e9sident Coty, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: A new clinical challenge","volume":"43","author":"Navarro","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: Importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jean, S.S., Harnod, D., and Hsueh, P.R. (2022). Global threat of carbapenem-resistant Gram-negative bacteria. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.823684"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bell, B.G., Schellevis, F., Stobberingh, E., Goossens, H., and Pringle, M. (2014). A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-13"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/QCO.0000000000000756","article-title":"Duration of antibiotic therapy for Enterobacterales and Pseudomonas aeruginosa: A review of recent evidence","volume":"34","author":"Reyes","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus 14 Days of antibiotic therapy for uncomplicated gram-negative bacteremia: A noninferiority randomized controlled trial","volume":"69","author":"Yahav","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: A randomized clinical trial","volume":"323","author":"Albrich","year":"2020","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cmi.2021.09.001","article-title":"Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: A randomized, controlled trial","volume":"28","author":"Molina","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","first-page":"101750","article-title":"Duration of antibiotic treatment for Gram-negative bacteremia. Systematic review and individual participant data (IPD) meta-analysis","volume":"55","author":"Turjeman","year":"2022","journal-title":"Eclininal Med."},{"key":"ref_11","unstructured":"HAS (2024, January 01). Antibioth\u00e9rapie des Infections \u00e0 Ent\u00e9robact\u00e9ries et \u00e0 Pseudomonas aeruginosa Chez l\u2019Adulte: Place des Carbapen\u00e8mes et de Leurs Alternatives. Mai 2019, mis \u00e0 jour Mars 2023. Available online: https:\/\/www.has-sante.fr\/jcms\/c_2968915\/fr\/antibiotherapie-des-infections-a-enterobacteries-et-a-pseudomonas-aeruginosa-chez-l-adulte-place-descarbapenemes-et-de-leurs-alternatives."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.idnow.2020.12.001","article-title":"Anti-infectious treatment duration: The SPILF and GPIP French guidelines and recommendations","volume":"52","author":"Gauzit","year":"2021","journal-title":"Infect. Dis. Now"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13063-018-2474-1","article-title":"7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: A pilot randomized clinical trial","volume":"19","author":"Daneman","year":"2018","journal-title":"Trials"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijantimicag.2011.07.016","article-title":"Antibiotic treatment duration for bloodstream infections in critically ill patients: A national survey of Canadian infectious diseases and critical care specialists","volume":"38","author":"Daneman","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijantimicag.2019.05.011","article-title":"Duration of therapy recommended for bacteraemic illness varies widely amongst clinicians","volume":"54","author":"Alwan","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"He, Y., Xu, J., Shang, X., Fang, X., Gao, C., Sun, D., Yao, L., Zhou, T., Pan, S., and Zou, X. (2022). Clinical characteristics and risk factors associated with ICU-acquired infections in sepsis: A retrospective cohort study. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.962470"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT)","volume":"50","author":"Torres","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13613-018-0444-0","article-title":"Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU","volume":"8","author":"Leone","year":"2018","journal-title":"Ann. Intensive Care"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bouza, E., Guillen-Zabala, H., Rojas, A., Canada, G., Cercenado, E., Sanchez-Carrillo, C., Diez, C., Puente, L., Munoz, P., and Galar, A. (2023). Comparative study of the etiology of nosocomial bacteremic pneumonia in ventilated and non ventilated patients: A 10-year experience in an institution. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.01517-23"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/cc10036","article-title":"Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: A prospective and observational multicenter study","volume":"15","author":"Magret","year":"2011","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: An expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijantimicag.2018.06.018","article-title":"Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum B-lactamase-producing Enterobacteriaceae","volume":"52","author":"Russo","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"The BALANCE Investigators (2025). Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. N. Engl. J. Med., 392, 1065\u20131078.","DOI":"10.1056\/NEJMoa2404991"},{"key":"ref_27","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST 2012) (2020, August 01). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 2.0. Available online: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_15.0_Breakpoint_Tables.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archinte.1962.03620240029006","article-title":"Gram-negative bacteremia: Etiology and ecology","volume":"110","author":"McCabe","year":"1962","journal-title":"Arch. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new simplified acute physiology score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Lemeshow","year":"1993","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfonction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/4\/358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:07:27Z","timestamp":1760029647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/4\/358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["antibiotics14040358"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14040358","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}